Selective estrogen receptor modulators (SERMs) in the practice;Szelektív ösztrogénreceptormodulátorok (SERM-ek) a gyakorlatban

Magyar Onkologia

Volumn 46, Issue 2, 2002, Pages 165-175

  Tamás, Nagykálnai ^a  

^a Onkoradiológiai Központ ^*  (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN; ESTROGEN RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

BREAST TUMOR; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; REVIEW;

BREAST NEOPLASMS; CORONARY DISEASE; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TOREMIFENE;

EID: 0036355218     PISSN: 00250244     EISSN: 20600399     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Barrett-Connor E, Cox DA. The potential of SERMs for reducing the risk of coronary heart disease. Trends Endocrinol Metab 10:320-325, 1999
2. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease and other considerations. Ann Rev Public Health 19:55-72, 1998
3. Beresford SA, Weiss NS, Voigt LF, et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349:458-461, 1997
4. Bjarnason NH, Haarbo J, Byrjalsen I, et al. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 96:1964-1969, 1997
5. Boss SM, Huster WJ, Neild JA, et al. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 177:1458-1464, 1997
6. Breuer B, Wallenstein S, Anderson R. Effect of tamoxifen on bone fractures in older nursing home residents. J Am Geriatr Soc 46:968-972, 1998
7. Brzozowski AM. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758, 1997
8. Buzdar AU, Marcus C, Holmes F, et al. Phase II evaluation of LY 156758 in metastatic breast cancer. Oncology 45:344-345, 1988
9. Cattaneo M. Tamoxifen reduces plasma homocysteine levels in healthy women. Obstet Gynecol 91:432-436, 1998
10. Cauley JA, Lucas FL, Kuller LH, et al. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA 276:1404-1408, 1996
11. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy. Combined reanalysis of data from 51 epidemiological studies involving 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350:1047-1059, 1997
12. Costantino JP, Kuller LH, Ives DG, et al. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 89:776-782, 1997
13. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifen on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281:2189-2197, 1999
14. Dancsó J, Cseh I, Fülöp V, és mtsai. Az ösztrogén jelátvitel és a szelektív ösztrogén receptor moduláció (SERM). Magy Nôorv Lapja 63:113-118, 2000
15. Decensi A, Robertson C, Ballardini B, et al. Effect of tamoxifen on lipoprotein(a) and Insulin-like Growth Factor-I (IGF-I) in healthy women. Eur J Cancer 35:596-600, 1999
16. Delmas P. Effects of raloxifen on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New Engl J Med 337:1641-1647, 1997
17. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351:1451-1467, 1998
18. Eastell R. Treatment of postmenopausal osteoporosis. New Engl J Med 338:736-746, 1998
19. Ettinger B. Raloxifene reduces the risk of incidental veratebral fractures: 24 months interim analysis. Osteoporosis Int 8(Suppl 11): Abstr OR-23, 1999
20. Fisher B, Costantino JP, Wickerham L, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371-1388, 1998
21. Gail MH, Costantino JP, Bryant J, et al. Weighing the risk and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829-1846, 1999
22. Glass CK, Rose DW, Rosenfeld MG. Nuclear receptor coactivators. Curr Opin Cell Biol 9:222-232, 1997
23. Gottardis MM, Jordan VC. The antitumor actions of keoxifene (raloxifene) and tamoxifen in the N-nitrosomethyl-urea-induced rat mammary carcinoma model. Cancer Res 47:4020-4024, 1987
24. Grey AB, Stapleton JP, Evans MC, et al. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 99:636-641, 1995
25. Gylling H, Pyrhonen S, Mantyla E, et al. Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer. J Clin Oncol 13:2900-2905, 1995
26. Harper MJK, Walpole AL. A new derivate of triphenylethylene: effect of implantation and mode of action in rats. J Reprod Fertil 13:101-119, 1967
27. Heaney RP, Draper MW. Raloxifene and estrogen: comparative bone-remodeling kinetics. J Clin Endocrinol Metab 82:3425-3429, 1997
28. Herd RJM, Balena R, Blake GM, et al. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study. Am J Med 103:92-99, 1997
29. Hosking D. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. New Engl J Med 338:485-492, 1998
30. Hulley S for the HERS Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613, 1998
31. Jensen EV, Jacobson HI. Basic guides to mechanism of estrogen action. Recent Prog Horm Res 18:387-414, 1962
32. Jordan VC. How does tamoxifen work? In: Tamoxifen for the Treatment and Prevention of Breast Cancer. Ed: Jordan VC. PRR, Melville, New York, pp. 257-263,1999
33. Jordan VC, Glusman JE, Eckert S, et al. Raloxifene reduces incident primary breast cancers. Integrated data from multicenter double blind, placebo controlled randomized trials in postmenopausal women. Breast Cancer Res Treat 50:227, 1998
34. Jordan VC, Phelps E, Lindgren JU. Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10:31-35, 1987
35. Jordan VC, Robinson SP. Species specific pharmacology of antiestrogens: role of metabolism. Fed Proc 46:1870-1874, 1987
36. Jordan VC. Incident primary breast cancer are reduced by raloxifene: integrated data from multicenter, doubleblind randomized trials in approx. 12,000 postmenopausal women. Proc ASCO 17:466, 1998
37. Jordan VC. Progress in the prevention of breast cancer: a concept to reality. J Steroid Biochem Molecular Biol 74:269-277, 2000
38. Jordan VC. Designer estrogens. Sci Amer 279:36-43, 1998
39. Kangas L. Review of the pharmacological properties of toremifene. J Steroid Biochem 36:191-195, 1990
40. Kauffman RF, Bean JS, Bensch WR. Effects of estrogen and raloxifene, a selective estrogen receptor modulator, in animal models of vascular injury. In: Estrogen and the Vessel Wall. Eds.: Rubanyi GM, Kauffman RF, Harwood Academic Publishers, 1998, pp 201-211
41. Kauffman RF, Bryant HU. Selective estrogen receptor modulators. Drug News Perspect 8:531-539, 1995
42. Kauffman RF. Hypercholesterolemic activity of raloxifene (LY 139481): pharmacological characterization as a selective estrogen receptor modulator. J Pharmacol Exp Ther 280:146-153, 1997
43. Kristensen B, Ejlertsen B, Dalgaard P, et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 12:992-997, 1994
44. Kuiper GGJM, Enmark E, Pelto-Huikko M, et al. Cloning a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925-5930, 1996
45. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer. Eight Cain memorial award lecture. Cancer Res 50:4177-4189, 1990
46. Levenson AS, Jordan VC. Selective oestrogen receptor modulation: molecular pharmacology for the millenium. Eur J Cancer 35:1628-1639, 1999
47. Love RR, Barden HS, Mazess RB, et al. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 154:2585-2588, 1994
48. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Int Med 115:860-864, 1991
49. MacDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br Med J 303:435-437, 1991
50. MacGregor JI, Jordan VC. Basic guide to the mechanism of antioestrogen action. Pharmacol Rev 50:151-196, 1998
51. Marttunen MB, Hietanen P, Tiitinen A, et al. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 83:1158-1162, 1998
52. McDonnell DP. The molecular pharmacology of SERMs. Trends Endocrin Metabol 10:301-311, 1999
53. Milla Santos A, Milla L, Rallo L, et al. Phase III study of toremifene vs tamoxifen in hormonal dependent advanced breast cancer (ABC): A randomized trial. Proc 11th ICACT, Paris, S09-05, 139, 2001
54. Morrow M, Jordan VC. Tamoxifen for breast cancer prevention: half an effect is better than none. Breast Diseases 10:25-26, 1999
55. Mosselman S, Polman J, Dijkema R. ERb: identification and characterization of a novel human estrogen receptor. FEBS Lett 392:49-53, 1996
56. Osborne CK, Hobbs K, Clark GM. Effects of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45:584-590, 1985
57. Paul S, Dean RA, Tracy RP, et al. Effects of raloxifene and hormone replacement therapy on homocysteine and C-reactive protein levels in postmenopausal women. Circulation 98:1-7, 1998
58. Pávó I, Jurida N. Szelektív ösztrogén receptor modulátorok (SERM). Új koncepció a postmenopausalis hormonpótlásban. Gyógyszereink (Suppl 1):35-40, 1998
59. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 352:98-101, 1998
60. Rutquist LE, Mattson A. Cardiac and thromboembolic morbidity among postmenopausal women in early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 85:1389-1406, 1993
61. Saarto T, Blomquist C, Ehnholm C, et al. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with nodepositive breast cancer. J Clin Oncol 14:429-433, 1996
62. Shiau AK. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95: 927-937, 1998
63. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11:657-666, 1997
64. Smith CL, O'Malley BW. Evolving concepts of selective estrogen receptor action: from basic science to clinical applications. Trends Endocrin Metabol 10:299-300, 1999
65. Taylor AL, Adams-Campbell LL, Wright Jr, JT. Risk/benefit assessment of tamoxifen to prevent breast cancer-still a work in progress? J Natl Cancer Inst 91:1792-1793, 1999
66. The Writing Group for the PEPI Trial: Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 276:1389-1396, 1996
67. Thiebaud D. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298-307, 1997
68. Update on SERMs. In: Medical Express Reports. The 8th Annual Meeting of the North American Menopausal Society (NAMS), Boston, MS, 4-6 Sept 1997
69. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 352:93-97, 1998
70. Vickers MR, Meade TW, Wilkes HC. Hormone replacement therapy and cardiovascular disease: the case for a randomized controlled trial. Ciba Found Symp 1991, 150-160, 1995
71. Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocrine-Related Cancer 7:17-28, 2000
72. Wakeling AE. The future of new pure antioestrogens in clinical breast cancer. Breast Cancer Res Treat 25:1-9, 1993
73. Walpole AL, Paterson E. Synthetic oestrogen in mammary cancer. Lancet ii:783-789, 1949
74. Walsh BW. The effect of raloxifene on markers of cardiovascular risk in healthy, postmenopausal women. JAMA 279:1445-1451, 1998
75. Wenger NK. Coronary heart disease: an older woman's major health risk. Br Med J 315:1085-1090, 1997
76. Wiernicki T, Glaserbrook A, Phillips DL, et al. Estrogen and a novel tissue selective estrogen receptor modulator raloxifene directly modulate vascular smooth muscle cell functions: implications in the cardioprotective mechanism of estrogen. Circulation 94:1278, 1996
77. Williams P, Shalmi M, Korsgaard N, et al. A partial estrogen receptor agonist with strong antiatherogenic properties without noticeable effect on reproductive tissue in cholestrol-fed female and male rabbits. Arterioscler Thromb Vasc Biol 17:2264-2272, 1997
78. Women's Health Initiative Study Group: Design of the women's health initiative clinical trial and observational study. Control Clin Trials 19:61-106, 1998
79. Woodward M, Lowe GDO, Rumley A, et al. Fibrinogen as a risk factor for coronary artery disease and mortality in middle-aged men and women. Eur Heart J 19:55-62, 1998